keyword
MENU ▼
Read by QxMD icon Read
search

Total PSA Free PSA

keyword
https://www.readbyqxmd.com/read/29779925/the-application-of-p2psa-and-prostate-health-index-in-prostate-cancer-detection-a-prospective-cohort-in-a-tertiary-medical-center
#1
Yung-Ting Cheng, Chih-Hung Chiang, Yeong-Shiau Pu, Shih Ping Liu, Yu-Chuang Lu, Yi-Kai Chang, Hong-Chiang Chang, Kuo-How Huang, Yuan-Ju Lee, Po-Ming Chow, Shih-Chun Hung, Chao-Yuan Huang
BACKGROUND/PURPOSE: Prostate specific antigen (PSA) with low specificity that causes unnecessary prostate biopsies increases clinical morbidities, psychological stress, and medical expenses. We aimed to test the accuracy and cutoff value of Prostate Health Index (PHI) in men for prostate cancer detection. METHODS: We prospectively enrolled 213 men who underwent prostate biopsy with PSA≦10 ng/ml or abnormal findings on digital rectal examination. Total PSA (tPSA), free PSA (fPSA) and p2PSA levels were measured by serum samples before prostate biopsy...
May 17, 2018: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/29748830/-give-me-five-ultra-hypofractionated-radiotherapy-for-localized-prostate-cancer-non-invasive-ablative-approach
#2
Giulia Marvaso, Giulia Riva, Delia Ciardo, Sara Gandini, Cristiana Fodor, Dario Zerini, Sarah Pia Colangione, Giorgia Timon, Stefania Comi, Raffaella Cambria, Federica Cattani, Ottavio De Cobelli, Roberto Orecchia, Barbara A Jereczek-Fossa
Ultra-hypofractionated radiotherapy (RT) is given over a shorter time with larger doses with respect to conventional fractionation in patients with localized prostate cancer (PCa). The use of hypofractionation is supported both from the radiobiological point of view (the low α/β-ratio in PCa and dose escalation) and from the rising number of clinical evidences. The aim of this study is to review our data regarding oncological outcomes, namely biochemical progression-free survival (b-PFS) and clinical progression-free survival (c-PFS), acute and long-term toxicities in patients treated with a ultra-hypofractionated RT...
May 10, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29741162/the-urinary-sarcosine-creatinine-ratio-is-a-potential-diagnostic-and-prognostic-marker-in-prostate-cancer
#3
Meng Wang, Lihui Zou, Jing Liang, Xin Wang, Dalei Zhang, Yuan Fang, Junhua Zhang, Fei Xiao, Ming Liu
BACKGROUND The aim of this study was to evaluate the role of the urinary sarcosine/creatinine ratio in the diagnosis and prognosis of prostate cancer, using a sarcosine oxidase assay. MATERIAL AND METHODS Urine samples were obtained from 203 patients with benign prostate hyperplasia (BPH) and 209 patients with prostate cancer. Levels of urinary sarcosine were measured using the sarcosine oxidase method. The urinary sarcosine/creatinine ratios were compared between the group of patients with BPH and the patients with prostate cancer...
May 9, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29734838/discordant-prostate-specific-antigen-test-results-despite-who-assay-standardization
#4
Martin Boegemann, Christian Arsov, Boris Hadaschik, Kathleen Herkommer, Florian Imkamp, Jerzy-Roch Nofer, Joachim Gerß, Peter Albers, Axel Semjonow
INTRODUCTION: Total PSA (tPSA) and free PSA (fPSA) are the most commonly used biomarkers for early detection of prostate cancer. Despite standardization efforts, many available PSA assays may still produce discordant results. In the present study, we compared four PSA assays calibrated to the WHO standards 96/670 and 96/668 for tPSA and fPSA, respectively. METHODS: Within the scope of the Prostate Cancer Early Detection Study Based on a ''Baseline'' PSA Value in Young Men (PROBASE), we tested tPSA and fPSA in serum samples from 50 patients in the four different PROBASE sites using four WHO-calibrated assays from Roche (Elecsys, Cobas), Beckman-Coulter (Access-II) and Siemens (ADVIA Centaur)...
May 1, 2018: International Journal of Biological Markers
https://www.readbyqxmd.com/read/29730198/long-term-outcomes-after-deferred-radical-prostatectomy-in-men-initially-managed-by-active-surveillance
#5
Rebecka Arnsrud Godtman, Max Schafferer, Carl-Gustaf Pihl, Johan Stranne, Jonas Hugosson
PURPOSE: To determine the long-term outcomes after deferred radical prostatectomy. MATERIAL AND METHODS: The study population consisted of all men with screening-detected prostate cancer who underwent deferred radical prostatectomy (n=132; 1 Jan 1995-31 Dec 2014) after active surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial. The last date of follow-up was 15 May 2017. Follow-up during active surveillance was performed with prostate-specific antigen (PSA)-tests every 3-6 months and repeat biopsies every 2-4 years...
May 3, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29727915/three-month-posttreatment-prostate-specific-antigen-level-as-a-biomarker-of-treatment-response-in-patients-with-intermediate-risk-or-high-risk-prostate-cancer-treated-with-androgen-deprivation-therapy-and-radiotherapy
#6
Alex K Bryant, Anthony V D'Amico, Paul L Nguyen, John P Einck, Christopher J Kane, Rana R McKay, Daniel R Simpson, Arno J Mundt, James D Murphy, Brent S Rose
BACKGROUND: Prostate-specific antigen (PSA) measurement after definitive radiotherapy (RT) and androgen deprivation therapy for localized prostate cancer has been proposed as an early prognostic biomarker. In the current study, the authors investigated the association between 3-month post-RT PSA level and biochemical progression-free survival (bPFS), prostate cancer-specific survival (PCSS), and overall survival (OS). METHODS: A total of 5783 patients with intermediate-risk or high-risk localized prostate cancer who were diagnosed between 2000 and 2015 and treated with RT and androgen deprivation therapy were identified from Veterans Affairs data...
May 4, 2018: Cancer
https://www.readbyqxmd.com/read/29725416/baseline-prostate-specific-antigen-levels-following-treatment-with-abiraterone-acetate-as-a-prognostic-factor-in-castration-resistant-prostate-cancer
#7
Tasuku Hiroshige, Yoshiro Eguchi, Osamu Yoshizumi, Katsuaki Chikui, Hisaji Kumagai, Yoshihiro Kawaguchi, Rei Onishi, Tokumasa Hayashi, Kouta Watanabe, Tomotaro Mitani, Koujiro Saito, Tsukasa Igawa
The aim of the present study was to investigate the prognostic factors associated with progression-free survival (PFS) and overall survival (OS) times in patients with castration-resistant prostate cancer (CRPC) who received treatment with abiraterone acetate (AA) in routine clinical settings. A total of 93 patients treated with AA between September 2014 and February 2017 were selected and their medical records were analyzed retrospectively. The median PFS time of docetaxel (DTX)-naïve patients was 171 days, and that of post-DTX patients was 56 days...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29718346/two-years-of-bicalutamide-monotherapy-in-patients-with-biochemical-relapse-after-radical-prostatectomy
#8
Teppei Okubo, Koji Mitsuzuka, Takuya Koie, Senji Hoshi, Shigeki Matsuo, Seiichi Saito, Norihiko Tsuchiya, Tomonori Habuchi, Chikara Ohyama, Yoichi Arai
Background: Salvage treatments for biochemical relapse (BCR) after radical prostatectomy (RP) have several problems in terms of indications or adverse events. We studied the possibility of 2 years of bicalutamide monotherapy for BCR after RP. Methods: Patients who showed BCR (prostate-specific antigen (PSA) ≥ 0.2 ng/ml) after RP were recruited. Protocol treatment was planned as 2 years of bicalutamide (80 mg/day) followed by observation. Protocol treatment failure was defined as PSA re-elevation of ≥0...
April 28, 2018: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29699372/prognostic-factors-for-hormone-sensitive-metastatic-prostate-cancer-impact-of-disease-volume
#9
Alshimaa Mahmoud Alhanafy, Fouad Zanaty, Reda Ibrahem, Suzan Omar
Background and Aim: The optimal management of metastatic hormone-sensitive prostate cancer has been controversial in recent years with introduction of upfront chemohormonal treatment based on results of several Western studies. This changing landscape has renewed interest in the concept “disease volume”, the focus of the present study is the Egyptian patients. Methods: Patients with hormone sensitive metastatic prostate cancer presenting at Menoufia University Hospital, Egypt, during the period from June 2013 to May 2016, were enrolled...
April 27, 2018: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29697929/impact-of-psa-density-of-transition-zone-as-a-potential-parameter-in-reducing-the-number-of-unnecessary-prostate-biopsies-in-patients-with-psa-levels-between-2-6-and-10-0-ng-ml
#10
Hugo A Socrates Castro, Wagner Iared, José Eduardo Mourão Santos, Raphael Sandes Solha, David Carlos Shigueoka, Sergio Aron Ajzen
PURPOSE: To assess the accuracy of prostate-specific antigen (PSA) adjusted for the transition zone volume (PSATZ) in predicting prostate cancer by comparing the ability of several PSA parameters in predicting prostate cancer in men with intermediate PSA levels of 2.6 - 10.0 ng/mL and its ability to reduce unnecessary biopsies. MATERIALS AND METHODS: This study included 656 patients referred for prostate biopsy who had a serum PSA of 2.6 - 10.0 ng/mL. Total prostate and transition zone volumes were measured by transrectal ultrasound using the prolate ellipsoid method...
April 10, 2018: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/29625755/-99m-technetium-based-prostate-specific-membrane-antigen-radioguided-surgery-in-recurrent-prostate-cancer
#11
Tobias Maurer, Stephanie Robu, Margret Schottelius, Kristina Schwamborn, Isabel Rauscher, Nynke S van den Berg, Fijs W B van Leeuwen, Bernhard Haller, Thomas Horn, Matthias M Heck, Jürgen E Gschwend, Markus Schwaiger, Hans-Jürgen Wester, Matthias Eiber
BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) can visualize metastatic lesions in recurrent prostate cancer (PC). However, reliable identification of small and/or atypically localized lesions during salvage surgery procedures is challenging. OBJECTIVE: To describe the technique, feasibility, and short-term outcomes of99m Technetium (99m Tc)-based PSMA-radioguided surgery (99m Tc-PSMA-RGS) for removal of recurrent PC lesions...
April 3, 2018: European Urology
https://www.readbyqxmd.com/read/29595681/value-of-free-total-prostate-specific-antigen-f-t-psa-ratios-for-prostate-cancer-detection-in-patients-with-total-serum-prostate-specific-antigen-between-4-and-10-ng-ml-a-meta-analysis
#12
Yan Huang, Zhen-Zhen Li, Ya-Liang Huang, Hong-Jun Song, You-Juan Wang
BACKGROUND: Prostate carcinoma is a common disease that occurs in men over 50 years old. Many studies have explored the effect of free/total prostate-specific antigen (f/t PSA) ratio in monitoring prostate cancer. We conducted a meta-analysis to identify the accuracy of the f/t PSA ratio in the diagnosis of prostate cancer in patients who have PSA levels of 4 to 10 ng/mL. METHODS: Databases searched included PubMed and OVID databases, from inception to March 2017, after a systematical review, sensitivity, specificity, and other measures of accuracy of the f/t PSA ratio in the diagnosis of prostate cancer were pooled...
March 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29573835/high-intensity-focused-ultrasound-therapy-for-the-treatment-of-prostate-cancer-medium-term-experience
#13
A Durán-Rivera, A Montoliu García, J Juan Escudero, P Garrido Abad, M Fernández Arjona, E López Alcina
INTRODUCTION: The treatment of localised prostate cancer seeks to minimise the impact on sexual function and urinary continence. In this respect, therapy with high-intensity focused ultrasound offers important results. We present our experience with this technique in 2 Spanish centres. MATERIAL AND METHODS: We conducted a retrospective review of 75 patients with localised prostate cancer treated with high-intensity focused ultrasound between March 2007 and July 2016...
March 21, 2018: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/29561434/meta-analysis-of-cdkn2a-methylation-to-find-its-role-in-prostate-cancer-development-and-progression-and-also-to-find-the-effect-of-cdkn2a-expression-on-disease-free-survival-prisma
#14
Zipei Cao, Lijuan Wei, Weizhi Zhu, Xuping Yao
BACKGROUND: Reduction of cyclin-dependent kinase inhibitor 2A (CDKN2A) (p16 and p14) expression through DNA methylation has been reported in prostate cancer (PCa). This meta-analysis was conducted to assess the difference of p16 and p14 methylation between PCa and different histological types of nonmalignant controls and the correlation of p16 or p14 methylation with clinicopathological features of PCa. METHODS: According to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement criteria, articles were searched in PubMed, Embase, EBSCO, Wanfang, and CNKI databases...
March 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29560520/changes-in-the-levels-of-testosterone-profile-over-time-in-relation-to-clinical-parameters-in-a-cohort-of-patients-with-prostate-cancer-managed-by-active-surveillance
#15
Ahmed S Zakaria, Alice Dragomir, Wassim Kassouf, Simon Tanguay, Armen Aprikian
OBJECTIVES: To characterize testosterone profile changes over time in a cohort of prostate cancer (PCa) patients managed with active surveillance (AS) and to assess its correlation with the initial disease characteristics and further progression. METHODS: We conducted retrospective chart review of PCa patients managed with AS. Patients were followed with PSA, total, free and bioavailable testosterone measurements, physical examination, and by repeat biopsies or periodic magnetic resonance imaging...
March 20, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29551263/-salvage-cryotherapy-of-prostate-cancer-after-failed-external-radiotherapy-and-brachytherapy-morbidity-and-mid-term-oncological-results
#16
A Gevorgyan, J-F Hétet, M Robert, V Duchattelle-Dussaule, L Corno, I Boulay, H Baumert
OBJECTIVE: To study the oncologic and functional results of salvage cryotherapy after failure of external radiotherapy and brachytherapy. MATERIALS AND METHODS: Patients treated by total salvage cryotherapy (3rd generation) in 2 centers (Groupe Hospitalier Saint-Joseph in Paris and Clinique Jule-Verne Nantes) in between January 2008 and April 2016 were included. The biochemical recurrence-free survival (BRFS) was calculated using the Phoenix criteria (PSA>nadir+2ng/mL)...
April 2018: Progrès en Urologie
https://www.readbyqxmd.com/read/29520847/detectable-end-of-radiation-prostate-specific-antigen-assists-in-identifying-men-with-unfavorable-intermediate-risk-prostate-cancer-at-high-risk-of-distant-recurrence-and-cancer-specific-mortality
#17
Jonathan Hayman, Ryan Phillips, Di Chen, Jamie Perin, Amol K Narang, Janson Trieu, Noura Radwan, Stephen Greco, Curtiland Deville, Todd McNutt, Daniel Y Song, Theodore L DeWeese, Phuoc T Tran
BACKGROUND: Undetectable End of Radiation PSA (EOR-PSA) has been shown to predict improved survival in prostate cancer (PCa). While validating the unfavorable intermediate-risk (UIR) and favorable intermediate-risk (FIR) stratifications among Johns Hopkins PCa patients treated with radiotherapy, we examined whether EOR-PSA could further risk stratify UIR men for survival. METHODS: A total of 302 IR patients were identified in the Johns Hopkins PCa database (178 UIR, 124 FIR)...
June 2018: Prostate
https://www.readbyqxmd.com/read/29497860/are-10-10-12-or-12-mm-prostate-biopsy-core-quality-control-cutoffs-reasonable
#18
Brunno C F Sanches, Ana Luiza Lalli, Wilmar Azal Neto, Athanase Billis, Leonardo Oliveira Reis
PURPOSE: To explore the role of prostate biopsy core length on prediction of index tumor clinical significance and localization on radical prostatectomy (RP) and time to recurrence, hypothesizing 10-, 10-12-, or > 12-mm minimum core as potential biopsy quality control. METHODS: Assessed 2424 prostate biopsy cores and corresponding RP of 202 patients submitted to the first set of 12 cores prostate biopsy between 2010 and 2015. Analyzed biopsy core length, age, prostate volume (PV), free and total PSA ratio, PSA density, RP index tumor clinical significance, extension, localization, surgical margins, and cancer control...
March 1, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29495138/diagnostic-performance-of-2-propsa-and-prostate-health-index-for-prostate-cancer-prospective-multi-institutional-study
#19
Hongzoo Park, Sang Wook Lee, Geehyun Song, Tae Wook Kang, Jae Hung Jung, Hyun Chul Chung, Sung Jin Kim, Chang Hoo Park, Jong Yeon Park, Tae Young Shin, In Bum Suh, Jeong Hyun Kim
BACKGROUND: We evaluated the clinical performance of [-2]proPSA (p2PSA) and its derivatives in predicting the presence and aggressiveness of prostate cancer (PCa) in Korean men. METHODS: A total of 246 men with total prostate-specific antigen (tPSA) ≥ 3.5 ng/mL who underwent their first prostate biopsy were included in this prospective, multicenter, observational study. Diagnostic accuracy of tPSA, free-to-total PSA ratio (%fPSA), p2PSA, %p2PSA, and the Beckman Coulter prostate health index (PHI) was assessed by receiver operating characteristic curve analyses and logistic regression analyses...
March 12, 2018: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/29460452/the-effect-of-digital-rectal-exam-on-the-4kscore-for-aggressive-prostate-cancer
#20
Michael A Maccini, Nicholas J Westfall, Adrie Van Bokhoven, Marshall Scott Lucia, Wendy Poage, Paul D Maroni, Shandra S Wilson, Leonard Michael Glodé, Paul Arangua, Jay Newmark, Mitchell Steiner, Priya N Werahera, Elward David Crawford
BACKGROUND: The 4Kscore is a new commercially available blood-based diagnostic test which predicts risk for aggressive, clinically significant prostate cancer on prostate biopsy. The 4Kscore is currently restricted to patients who have not had a digital rectal exam (DRE) in the previous 96 h, owing to prior mixed data suggesting that prostate specific antigen (PSA) isoforms may increase by a statistically significant-if not necessarily clinically significant-amount shortly after DRE...
May 2018: Prostate
keyword
keyword
68976
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"